Humacyte, Inc. (HUMA) Stock Analysis
A live, multi-source view of Humacyte, Inc. (HUMA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Sector: Healthcare · Industry: Biotechnology · United States · 184 employees · humacyte.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Humacyte, Inc. (HUMA) had a market capitalization of $168.0M (forward -2.4) and a beta of 2.45; the shares traded in a 52-week range of $0.53 – $2.55 (-57.1% over the year).
- Market cap
- $168.0M
- Enterprise value
- $155.0M
- Forward P/E
- -2.4
- Price / book
- 11.63
- EPS (trailing)
- $-0.52
- EPS (forward)
- $-0.25
- Payout ratio
- 0.0%
- 52-week range
- $0.53 – $2.55
- 52-week change
- -57.1%
- Beta
- 2.45
- Average volume
- 11.0M
- Shares outstanding
- 277.8M
- Short % of float
- 11.57%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Humacyte, Inc. (HUMA) last closed at $0.58 (the last completed close before that scan).
Technicals at the scan: RSI 42 (neutral territory), price -8.1% versus its 20-day average, 20-day versus 50-day average spread -6.0%, MACD histogram -0.00.
Sentiment inputs: StockTwits 67% bullish; Reddit mentions 0% over 24 hours; analyst consensus score 75/100.
Next scheduled company event: in 63 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 3 buys and 2 sells of HUMA; corporate insiders filed 2 buys and 0 sells (2 distinct filers, latest disclosure 2026-08-21). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Tommy Tuberville (3B/2S), Keith Anthony Jones (2B/0S). Who is trading what
RapidTradeView pick record
HUMA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Humacyte, Inc. (HUMA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell HUMA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.